Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

105.06 +2.43 (+2.37%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
65 66 Next >
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued. 
Via InvestorPlace
Topics Economy
Exposures Economy
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Novo Nordisk has found that its diabetes drug, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues. 
Via Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector. 
Via Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations. 
Via Benzinga
FDA Rejects Novo Nordisk's Weekly Insulin, Requests Information Related To Manufacturing Process, Type 1 Diabetes
The FDA has issued a Complete Response Letter to Novo Nordisk's Biologics License Application for once-weekly basal insulin icodec. Novo Nordisk aims to address the FDA's requests but anticipates... 
Via Benzinga
Exposures Product Safety
Will NVO Provide Any Buying Opportunity?
Novo Nordisk A/S, a healthcare company engages in the research, development, manufacture & marketing of the pharmaceutical products worldwide. 
Via Talk Markets
Looking for growth without the hefty price tag? Consider NYSE:NVO.
NYSE:NVO is showing decent growth, but is still valued reasonably. 
Via Chartmill
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Vivani Medical plans to start the first clinical study of the NPM-115 program in Australia in Q4 2024. The study will evaluate a 6-month GLP-1 implant for chronic weight management in obese or... 
Via Benzinga
Chipotle Just Did a Stock Split. History Says This Is What Might Happen Next.
Big-name stocks that have split their shares in recent years have generally done fairly well afterward. 
Via The Motley Fool
Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
Jim Cramer has identified eight companies that could potentially reach a market cap of $1 trillion, including Elon Musk's Tesla, and Eli Lilly. 
Via Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
Investors might want to consider the top pharma stocks in the current environment as they are beating most others. 
Via InvestorPlace
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
A study shows that only one in four U.S. patients prescribed Novo Nordisk's weight-loss drugs Wegovy or Ozempic remain on the medication after two years, raising concerns about long-term adherence. 
Via Benzinga
Stay Away: Why Ginkgo Bioworks Stock Is Not for the Faint-Hearted
Ginkgo Bioworks stock is down, but this doesn't mean it's a bargain as Ginkgo Bioworks faces a serious delisting threat. 
Via InvestorPlace
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been 
Via MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases. 
Via InvestorPlace
3 Stocks With the Potential to 10X Your Money
These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost. 
Via InvestorPlace
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
This pharma company is posting double-digit revenue growth. 
Via The Motley Fool
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Eli Lilly and Co has emerged victorious in the weight loss drug competition, in a recent study. The study found that patients on Lilly's Mounjaro lost more weight than those on Novo Nordisk's Ozempic. 
Via Benzinga
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
Patients lost more more weight on Mounjaro than Ozempic. 
Via Investor's Business Daily
3 Overlooked Giants-in-the-Making for Patient Investors
Consider buying into these overlooked growth stocks for long-term profits that will help to boost a portfolio and deliver riches. 
Via InvestorPlace
Novartis Stock Generating Improved Relative Strength
Top and bottom line growth moved higher in Novartis' most recent quarter. EPS rose 17% to $1.80. Revenue increased 10% to $12.1 billion. 
Via Investor's Business Daily
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
The 7 Best Under $10 Stocks to Buy in July 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now. 
Via InvestorPlace
Copper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points
Southern Copper and Agnico Eagle surged above early entries. 
Via Investor's Business Daily
MarketBeat Week in Review – 7/1 - 7/5
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season 
Via MarketBeat
Topics Economy
Exposures Interest Rates
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
A study finds that GLP-1 treatments, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, significantly reduce the risk of ten obesity-related cancers in type 2 diabetes patients, highlighting... 
Via Benzinga
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches in financial categorization and highlights similar issues with Novartis... 
Via Benzinga
Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review
However, small caps fell. Cooling economic data raised rate-cut hopes. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Is It Too Late to Buy Novo Nordisk Stock?
It's possible for investors to be too late to the party with a stock -- can Novo Nordisk's party keep rolling? 
Via The Motley Fool
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
Vertex Pharmaceuticals likely has a breakthrough medicine on its hands. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.